JP2023513793A5 - - Google Patents

Info

Publication number
JP2023513793A5
JP2023513793A5 JP2022549144A JP2022549144A JP2023513793A5 JP 2023513793 A5 JP2023513793 A5 JP 2023513793A5 JP 2022549144 A JP2022549144 A JP 2022549144A JP 2022549144 A JP2022549144 A JP 2022549144A JP 2023513793 A5 JP2023513793 A5 JP 2023513793A5
Authority
JP
Japan
Prior art keywords
alkyl
independently
heterocycloalkyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513793A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/018038 external-priority patent/WO2021163627A1/en
Publication of JP2023513793A publication Critical patent/JP2023513793A/ja
Publication of JP2023513793A5 publication Critical patent/JP2023513793A5/ja
Pending legal-status Critical Current

Links

JP2022549144A 2020-02-14 2021-02-12 大環状ulk1/2阻害剤 Pending JP2023513793A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977039P 2020-02-14 2020-02-14
US62/977,039 2020-02-14
PCT/US2021/018038 WO2021163627A1 (en) 2020-02-14 2021-02-12 Macrocyclic ulk1/2 inhibitors

Publications (2)

Publication Number Publication Date
JP2023513793A JP2023513793A (ja) 2023-04-03
JP2023513793A5 true JP2023513793A5 (cg-RX-API-DMAC10.html) 2024-02-20

Family

ID=77292762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549144A Pending JP2023513793A (ja) 2020-02-14 2021-02-12 大環状ulk1/2阻害剤

Country Status (8)

Country Link
US (1) US12594277B2 (cg-RX-API-DMAC10.html)
EP (1) EP4103183A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023513793A (cg-RX-API-DMAC10.html)
KR (1) KR20220153582A (cg-RX-API-DMAC10.html)
CN (1) CN115515588A (cg-RX-API-DMAC10.html)
AU (1) AU2021221162A1 (cg-RX-API-DMAC10.html)
CA (1) CA3171185A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021163627A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021216440A1 (en) * 2020-04-20 2021-10-28 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
US20230332243A1 (en) * 2020-09-30 2023-10-19 Salk Institute For Biological Studies Patient selection biomarkers for treatment with ulk inhibitors
WO2024017251A1 (zh) * 2022-07-18 2024-01-25 江苏恒瑞医药股份有限公司 抑制并诱导egfr降解的大环类化合物、其制备方法及其在医药上的应用
WO2024017258A1 (zh) * 2022-07-19 2024-01-25 百极弘烨(南通)医药科技有限公司 Egfr小分子抑制剂、含其的药物组合物及其用途
WO2024233766A1 (en) * 2023-05-10 2024-11-14 Erasca, Inc. Macrocyclic ulk1/2 inhibitors and their use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005049021A1 (en) 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
US20060069110A1 (en) 2004-09-27 2006-03-30 Andersen Denise L Substituted heterocyclic compounds and methods of use
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
WO2007028445A1 (en) 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
DK2089369T3 (da) 2006-10-19 2011-05-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
US20100130496A1 (en) 2007-04-12 2010-05-27 F. Hoffmann-La Roche Ag Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
WO2008140421A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Heterocycloalkyl substituted pyrimidine derivatives
US8461147B2 (en) 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
WO2009083185A2 (en) 2007-12-28 2009-07-09 Fovea Pharmaceuticals Sa Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders
CA2723205C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
CA2722326A1 (en) * 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2009158431A2 (en) 2008-06-25 2009-12-30 Irm Llc Compounds and compositions as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2729121C (en) * 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
WO2010146132A1 (en) 2009-06-18 2010-12-23 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
WO2011084523A2 (en) 2009-12-15 2011-07-14 The Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
SG10201500124VA (en) 2010-01-08 2015-03-30 Agency Science Tech & Res Methods and Compositions for Treating Cancer
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
US20130252950A1 (en) 2010-09-23 2013-09-26 President And Fellows Of Harvard College Targeting mtor substrates in treating proliferative diseases
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
US8691777B2 (en) 2011-01-27 2014-04-08 Emory University Combination therapy
US20120244209A1 (en) 2011-03-02 2012-09-27 Roth Jack A Tusc2 therapies
KR20130131461A (ko) 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
US20140343128A1 (en) 2011-11-15 2014-11-20 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway
US9073944B2 (en) 2012-02-21 2015-07-07 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
WO2014062621A1 (en) 2012-10-15 2014-04-24 Stc.Unm Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US20150328193A1 (en) 2012-12-17 2015-11-19 The Brigham And Women's Hospital, Inc. Treatment of mtor hyperactive related diseases and disorders
CN103059030B (zh) 2012-12-28 2015-04-29 北京师范大学 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
HK1218249A1 (zh) 2013-01-25 2017-02-10 Rigel Pharmaceuticals, Inc. 用於治疗炎症性肠道疾病的化合物和方法
BR112015030518A2 (pt) 2013-06-05 2017-08-29 Salk Inst For Biological Studi Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12)
CN106536503B (zh) 2014-04-18 2019-09-06 北京澳合药物研究院有限公司 一种酪氨酸激酶抑制剂及其用途
US10053458B2 (en) 2014-06-17 2018-08-21 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
ES2914099T3 (es) 2014-08-25 2022-06-07 Salk Inst For Biological Studi Inhibidores novedosos de ULK1 y métodos de uso de los mismos
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
CN105524045B (zh) 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
WO2016090079A1 (en) 2014-12-05 2016-06-09 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN106188029B (zh) 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
WO2016196393A2 (en) 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof
US20170038387A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
CN105801603B (zh) 2016-04-13 2018-10-02 成都倍特药业有限公司 一种具有大环结构的alk抑制剂及其制备方法
CA3040173A1 (en) 2016-10-18 2018-04-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders
US11180482B2 (en) 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
JP6684700B2 (ja) 2016-12-26 2020-04-22 アイシン精機株式会社 乗員検知装置
EP3620457A4 (en) 2017-05-02 2021-01-06 Korea Research Institute of Chemical Technology PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
HRP20231310T1 (hr) 2019-05-10 2024-02-02 Deciphera Pharmaceuticals, Llc Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
ES3072710T3 (en) 2019-06-17 2026-07-03 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
CA3171187A1 (en) 2020-02-14 2021-08-19 Salk Institute For Biological Studies Inhibitors of ulk1/2 and methods of using same
WO2021163633A1 (en) 2020-02-14 2021-08-19 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
WO2021216440A1 (en) 2020-04-20 2021-10-28 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
US20230332243A1 (en) 2020-09-30 2023-10-19 Salk Institute For Biological Studies Patient selection biomarkers for treatment with ulk inhibitors

Similar Documents

Publication Publication Date Title
JP2024514223A5 (cg-RX-API-DMAC10.html)
JP2020007311A5 (cg-RX-API-DMAC10.html)
JP2023502441A5 (cg-RX-API-DMAC10.html)
JP2023535453A5 (cg-RX-API-DMAC10.html)
JP2022515197A5 (cg-RX-API-DMAC10.html)
JP2025524914A5 (cg-RX-API-DMAC10.html)
JP2022534426A5 (cg-RX-API-DMAC10.html)
JP2019529444A5 (cg-RX-API-DMAC10.html)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
JP2021523221A5 (cg-RX-API-DMAC10.html)
JP2009526034A5 (cg-RX-API-DMAC10.html)
JP2022522694A5 (cg-RX-API-DMAC10.html)
JP2023511349A5 (cg-RX-API-DMAC10.html)
JP2020514388A5 (cg-RX-API-DMAC10.html)
JP2005523922A5 (cg-RX-API-DMAC10.html)
JP2017536395A5 (cg-RX-API-DMAC10.html)
JP2023531709A5 (cg-RX-API-DMAC10.html)
JP2012517428A5 (cg-RX-API-DMAC10.html)
JP2015500795A5 (cg-RX-API-DMAC10.html)
JP2023533203A5 (cg-RX-API-DMAC10.html)
JP2022537521A5 (cg-RX-API-DMAC10.html)
JP2010530403A5 (cg-RX-API-DMAC10.html)
JP2010501003A5 (cg-RX-API-DMAC10.html)
JP2022526220A5 (cg-RX-API-DMAC10.html)
JP2023101521A5 (cg-RX-API-DMAC10.html)